Carbone P P, Costello W
Cancer Treat Rep. 1976 Feb;60(2):193-8.
In four randomized controlled clinical trials with DTIC involving patiens with malignant melanoma, the Eastern Cooperative Oncology Group has seen a consistent objective response rate of 16%. A study of combinations of DTIC with two nitrosoureas indicated no additive effect. Survival and response were strongly correlated with sex, ambulatory status, and site of disease involvement. As secondary treatment DTIC was less effective, indicating only a 3% response rate. Survival benefit could be related to response. Among the ten largest contributors of patients, response rates varied from 3% to 40%. Similarly, while the overall response rate was not different for the combinations as compared to DTIC alone, the variation noted from study to study reflects the need for controlled randomized trials of chemotherapy for patients with malignant melanoma.
在四项涉及恶性黑色素瘤患者使用达卡巴嗪（DTIC）的随机对照临床试验中，东部肿瘤协作组观察到一致的客观缓解率为16%。一项关于达卡巴嗪与两种亚硝基脲联合使用的研究表明没有相加效应。生存和缓解与性别、活动状态及疾病受累部位密切相关。作为二线治疗，达卡巴嗪效果较差，仅显示3%的缓解率。生存获益可能与缓解有关。在十大患者贡献者中，缓解率从3%到40%不等。同样，虽然联合用药与单独使用达卡巴嗪相比总体缓解率没有差异，但不同研究中观察到的差异反映了对恶性黑色素瘤患者进行化疗对照随机试验的必要性。
